

Press release
Lund 10 May 2021

Scandinavian ChemoTech will launch a feasibility study to investigate the possibility of starting a clinical program focusing on pancreatic cancer

ChemoTech's Board of Directors has today decided to begin a feasibility study along with a group of leading specialists in pancreatic cancer in the US and Europe in order to create an international clinical collaboration.

Last year, ChemoTech's technology for bone cancer was able to treat its first patient with deep-seated tumours. As the pancreas is also a deep-seated organ, the Company has now decided that this cancer indication may also be suitable for treatment with ChemoTech's technology and should thus be seen as a prioritised indication. Today, the conditions for patients with pancreatic cancer are poor and there are few successful treatment methods.

In 2018, there were 460,000 cases of pancreatic cancer around the world and the same year, 432,000 patients died of this very difficult-to-treat disease. Therefore, there is a great need for better treatments that result in a longer life with improved quality of life for these patients.

The more aggressive Irreversible electroporation, so-called IRE, has for some time been used for pancreatic cancer with mixed results. ChemoTech aims to, after a successful feasibility study, establish a sufficiently large interest in starting a Phase II study with the aim of studying safety and efficacy in the treated patients.

"It is incredibly exciting to start this feasibility study, which indicates that the interest in our TSE technology for deep-seated tumours has spread. It will be very interesting to see what response ChemoTech will have to this decision during the LSI Emerging Medtech Summit 2021 in California later this week"- says Mohan Frick, CEO Scandinavian ChemoTech

For reference data:

<https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21492>

For more information, please contact:
Mohan Frick, CEO

+46 (0)10-218 93 00
info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00,
E-mail: certifiedadviser@penser.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Monday 10th of May 2021 at 14.00 (CET).

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se